# LifeStance Health Group, Inc.: financial statements, quarterly

LFST · Nasdaq · CIK 1845257 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lfst.md) · [Financials](/companies/lfst/financials.md) · [Filings](/companies/lfst/filings.md) · [Insiders](/companies/lfst/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lfst/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [263](/filings/0000950170-24-123376.md) | [281 d](/filings/0001193125-26-071462.md) | [300](/filings/0000950170-25-065806.md) | [312](/filings/0000950170-25-105096.md) | [313](/filings/0001193125-25-269712.md) | [325 d](/filings/0001193125-26-071462.md) | [333](/filings/0001193125-26-211814.md) | [345](/filings/0001193125-26-338107.md) | [364](/filings/0001193125-25-269712.md) | [382 d](/filings/0001193125-26-071462.md) | [403](/filings/0001193125-26-211814.md) | [435](/filings/0001193125-26-338107.md) |
| Selling, general and administrative | $m | [131](/filings/0000950170-24-123376.md) | [93.4 d](/filings/0001193125-26-071462.md) | [88.9](/filings/0000950170-25-065806.md) | [95.2](/filings/0000950170-25-105096.md) | [85.3](/filings/0001193125-25-269712.md) | [93.7 d](/filings/0001193125-26-071462.md) | [94.4](/filings/0001193125-26-211814.md) | [97.4](/filings/0001193125-26-338107.md) | [95.6](/filings/0001193125-25-269712.md) | [94.8 d](/filings/0001193125-26-071462.md) | [100](/filings/0001193125-26-211814.md) | [108](/filings/0001193125-26-338107.md) |
| Operating income | $m | [(74.4)](/filings/0000950170-24-123376.md) | [(32.3) d](/filings/0001193125-26-071462.md) | [(16.8)](/filings/0000950170-25-065806.md) | [(15.9)](/filings/0000950170-25-105096.md) | [0.0](/filings/0001193125-25-269712.md) | [1.1 d](/filings/0001193125-26-071462.md) | [1.6](/filings/0001193125-26-211814.md) | [(3.0)](/filings/0001193125-26-338107.md) | [7.4](/filings/0001193125-25-269712.md) | [18.1 d](/filings/0001193125-26-071462.md) | [22.3](/filings/0001193125-26-211814.md) | [30.7](/filings/0001193125-26-338107.md) |
| Interest expense | $m | [5.5](/filings/0000950170-24-123376.md) | [5.5 d](/filings/0001193125-26-071462.md) | [5.9](/filings/0000950170-25-065806.md) | [5.8](/filings/0000950170-25-105096.md) | [5.4](/filings/0001193125-25-269712.md) | [9.4 d](/filings/0001193125-26-071462.md) | [3.1](/filings/0001193125-26-211814.md) | [2.9](/filings/0001193125-26-338107.md) | [2.8](/filings/0001193125-25-269712.md) | [2.9 d](/filings/0001193125-26-071462.md) | [1.8](/filings/0001193125-26-211814.md) | [2.6](/filings/0001193125-26-338107.md) |
| Income tax | $m | [(16.4)](/filings/0000950170-24-123376.md) | [6.6 d](/filings/0001193125-26-071462.md) | [0.4](/filings/0000950170-25-065806.md) | [0.7](/filings/0000950170-25-105096.md) | [0.6](/filings/0001193125-25-269712.md) | [(1.8) d](/filings/0001193125-26-071462.md) | [(2.2)](/filings/0001193125-26-211814.md) | [(2.2)](/filings/0001193125-26-338107.md) | [3.5](/filings/0001193125-25-269712.md) | [3.5 d](/filings/0001193125-26-071462.md) | [5.5](/filings/0001193125-26-211814.md) | [3.8](/filings/0001193125-26-338107.md) |
| Net income | $m | [(61.6)](/filings/0000950170-24-123376.md) | [(45.0) d](/filings/0001193125-26-071462.md) | [(21.1)](/filings/0000950170-25-065806.md) | [(23.3)](/filings/0000950170-25-105096.md) | [0.7](/filings/0001193125-26-211814.md) | [(7.1) d](/filings/0001193125-26-071462.md) | [0.7](/filings/0001193125-26-211814.md) | [(3.8)](/filings/0001193125-26-338107.md) | [1.1](/filings/0001193125-25-269712.md) | [11.7 d](/filings/0001193125-26-071462.md) | [14.2](/filings/0001193125-26-211814.md) | [23.6](/filings/0001193125-26-338107.md) |

- Revenue: us-gaap:Revenues
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [42.6](/filings/0000950170-23-061118.md) | [78.8](/filings/0000950170-25-029100.md) | [49.5](/filings/0000950170-24-056989.md) | [87.0](/filings/0000950170-24-094105.md) | [103](/filings/0000950170-24-123376.md) | [155](/filings/0001193125-26-071462.md) | [134](/filings/0000950170-25-065806.md) | [189](/filings/0000950170-25-105096.md) | [204](/filings/0001193125-25-269712.md) | [249](/filings/0001193125-26-338107.md) | [195](/filings/0001193125-26-211814.md) | [226](/filings/0001193125-26-338107.md) |
| Current assets | $m | [264](/filings/0000950170-23-061118.md) | [226](/filings/0000950170-25-029100.md) | [244](/filings/0000950170-24-056989.md) | [278](/filings/0000950170-24-094105.md) | [287](/filings/0000950170-24-123376.md) | [313](/filings/0001193125-26-071462.md) | [305](/filings/0000950170-25-065806.md) | [359](/filings/0000950170-25-105096.md) | [360](/filings/0001193125-25-269712.md) | [416](/filings/0001193125-26-338107.md) | [356](/filings/0001193125-26-211814.md) | [378](/filings/0001193125-26-338107.md) |
| Total assets | $m | [2,175](/filings/0000950170-23-061118.md) | [2,110](/filings/0000950170-25-029100.md) | [2,106](/filings/0000950170-24-056989.md) | [2,119](/filings/0000950170-24-094105.md) | [2,108](/filings/0000950170-24-123376.md) | [2,118](/filings/0001193125-26-071462.md) | [2,105](/filings/0000950170-25-065806.md) | [2,147](/filings/0000950170-25-105096.md) | [2,149](/filings/0001193125-25-269712.md) | [2,204](/filings/0001193125-26-338107.md) | [2,146](/filings/0001193125-26-211814.md) | [2,181](/filings/0001193125-26-338107.md) |
| Current liabilities | $m | [241](/filings/0000950170-23-061118.md) | [203](/filings/0000950170-25-029100.md) | [207](/filings/0000950170-24-056989.md) | [228](/filings/0000950170-24-094105.md) | [218](/filings/0000950170-24-123376.md) | [229](/filings/0001193125-26-071462.md) | [207](/filings/0000950170-25-065806.md) | [242](/filings/0000950170-25-105096.md) | [229](/filings/0001193125-25-269712.md) | [252](/filings/0001193125-26-338107.md) | [240](/filings/0001193125-26-211814.md) | [275](/filings/0001193125-26-338107.md) |
| Total liabilities | $m | [720](/filings/0000950170-23-061118.md) | [681](/filings/0000950170-25-029100.md) | [677](/filings/0000950170-24-056989.md) | [689](/filings/0000950170-24-094105.md) | [671](/filings/0000950170-24-123376.md) | [672](/filings/0001193125-26-071462.md) | [648](/filings/0000950170-25-065806.md) | [673](/filings/0000950170-25-105096.md) | [656](/filings/0001193125-25-269712.md) | [683](/filings/0001193125-26-338107.md) | [668](/filings/0001193125-26-211814.md) | [704](/filings/0001193125-26-338107.md) |
| Long-term debt | $m | [248](/filings/0000950170-23-061118.md) | [280](/filings/0000950170-25-029100.md) | [280](/filings/0000950170-24-056989.md) | [279](/filings/0000950170-24-094105.md) | [279](/filings/0000950170-24-123376.md) | [280](/filings/0001193125-26-071462.md) | [276](/filings/0000950170-25-065806.md) | [273](/filings/0000950170-25-105096.md) | [269](/filings/0001193125-25-269712.md) | [266](/filings/0001193125-26-338107.md) | [262](/filings/0001193125-26-211814.md) | [259](/filings/0001193125-26-338107.md) |
| Current portion of debt | $m | [2.6](/filings/0000950170-23-061118.md) | [2.9](/filings/0000950170-25-029100.md) | [2.9](/filings/0000950170-24-056989.md) | [2.9](/filings/0000950170-24-094105.md) | [2.9](/filings/0000950170-24-123376.md) | [7.3](/filings/0001193125-26-071462.md) | [9.1](/filings/0000950170-25-065806.md) | [10.9](/filings/0000950170-25-105096.md) | [12.7](/filings/0001193125-25-269712.md) | [14.5](/filings/0001193125-26-338107.md) | [18.1](/filings/0001193125-26-211814.md) | [14.5](/filings/0001193125-26-338107.md) |
| Shareholders' equity | $m | [1,455](/filings/0000950170-23-061118.md) | [1,429](/filings/0000950170-25-029100.md) | [1,429](/filings/0000950170-24-056989.md) | [1,430](/filings/0000950170-24-094105.md) | [1,437](/filings/0000950170-24-123376.md) | [1,446](/filings/0001193125-26-071462.md) | [1,457](/filings/0000950170-25-065806.md) | [1,474](/filings/0000950170-25-105096.md) | [1,493](/filings/0001193125-25-269712.md) | [1,521](/filings/0001193125-26-338107.md) | [1,477](/filings/0001193125-26-211814.md) | [1,477](/filings/0001193125-26-338107.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(25.4) d](/filings/0000950170-24-123376.md) | [16.8 d](/filings/0001193125-26-071462.md) | [(21.8)](/filings/0000950170-25-065806.md) | [44.1 d](/filings/0000950170-25-105096.md) | [22.7 d](/filings/0001193125-25-269712.md) | [62.3 d](/filings/0001193125-26-071462.md) | [(3.1)](/filings/0001193125-26-211814.md) | [64.4 d](/filings/0001193125-26-338107.md) | [27.3 d](/filings/0001193125-25-269712.md) | [57.6 d](/filings/0001193125-26-071462.md) | [33.1](/filings/0001193125-26-211814.md) | [99.9 d](/filings/0001193125-26-338107.md) |
| Capital expenditure | $m | [9.8 d](/filings/0000950170-24-123376.md) | [11.4 d](/filings/0001193125-26-071462.md) | [5.1](/filings/0000950170-25-065806.md) | [5.1 d](/filings/0000950170-25-105096.md) | [5.1 d](/filings/0001193125-25-269712.md) | [6.3 d](/filings/0001193125-26-071462.md) | [7.2](/filings/0001193125-26-211814.md) | [7.8 d](/filings/0001193125-26-338107.md) | [10.3 d](/filings/0001193125-25-269712.md) | [10.9 d](/filings/0001193125-26-071462.md) | [10.8](/filings/0001193125-26-211814.md) | [12.0 d](/filings/0001193125-26-338107.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-211814.md) | [0.0 d](/filings/0001193125-26-338107.md) | not reported | not reported | [49.1](/filings/0001193125-26-211814.md) | [48.5 d](/filings/0001193125-26-338107.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.4](/filings/0000950170-23-061118.md) | [361](/filings/0000950170-24-056989.md) | [363](/filings/0000950170-24-094105.md) | [372](/filings/0000950170-24-123376.md) | [376](/filings/0000950170-25-065806.md) | [379](/filings/0000950170-25-105096.md) | [380](/filings/0001193125-25-269712.md) | [391](/filings/0001193125-26-211814.md) | [387](/filings/0001193125-26-338107.md) | [389](/filings/0001193125-25-269712.md) | [395](/filings/0001193125-26-211814.md) | [387](/filings/0001193125-26-338107.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 382,055,609 at 2026-07-29, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338107.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.